Physician profile
Greg Link
NPI 1871692798
$2,134.55
in general payments reported to CMS, 2019-2025
27 companies · $939 in 2025
The $939 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $307 · 2023: $358 · 2024: $531 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.40 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $262.10 | 2024-2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $224.92 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Neurocrine Biosciences, INC. | $202.35 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $145.08 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $139.32 | 2022-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $113.51 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $103.69 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $102.19 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $81.46 | 2022-2025 | Rybelsus, Ozempic |
| Lundbeck LLC | $78.17 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $69.06 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $34.85 | 2022 | |
| Pfizer INC. | $32.61 | 2025 | |
| Exact Sciences Corporation | $30.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $30.33 | 2022 | |
| Amgen INC. | $24.80 | 2022-2024 | Prolia, Evenity |
| Inspire Medical Systems, INC. | $24.24 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $21.33 | 2024 | Auvelity |
| Edwards Lifesciences Corporation | $20.39 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.97 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $16.78 | 2024 | Qelbree |
| Avanir Pharmaceuticals, INC. | $16.55 | 2022 | |
| Mylan Specialty L.P. | $16.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.86 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.46 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.